LivaNova is partnering with Verily to offer a wearable device and app with which they hope to gather information about measures of depression as part of an ongoing clinical study.
The RECOVER clinical study is evaluating the effectiveness of Vagus Nerve Stimulation Therapy (VNS Therapy) in patients with Difficult-to-Treat-Depression (DTD).
The companies aim to gather quantitative data regarding patient behaviour using Verily-developed technology and analytics to deepen understanding of depressive episodes and patient response to treatment.
Patients on the trial could be offered the Verily Study Watch, a wearable designed to capture physiological and environmental data, and a Verily mobile phone app.
Dr. William Marks, Verily’s head of clinical science and neurology, said: “Finding new solutions to help those who suffer from Difficult-to-Treat Depression promises to truly transform patients’ lives.”
“We look forward to working with LivaNova to gather additional data and evidence on VNS Therapy for Difficult-to-Treat Depression with the potential for collaboration on other areas of research in the future.”
Meanwhile, Damien McDonald, LivaNova CEO, said: “The goal of the RECOVER study is to assess how VNS Therapy can offer patients with DTD relief from their symptoms and improve their quality of life.”
“Through this collaboration with Verily, we can build on our work to study depression and better understand the complex elements that contribute to the disorder, enhancing our ability to treat the patients who battle it.”